GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Total Current Liabilities

Acrivon Therapeutics (Acrivon Therapeutics) Total Current Liabilities : $9.04 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Acrivon Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $9.04

Acrivon Therapeutics Total Current Liabilities Historical Data

The historical data trend for Acrivon Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Total Current Liabilities Chart

Acrivon Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
0.61 2.91 6.52 13.30

Acrivon Therapeutics Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.68 7.02 9.30 13.30 9.04

Acrivon Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Acrivon Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=8.566+0.877
+Other Current Liabilities+Current Deferred Liabilities
=3.86+0
=13.30

Acrivon Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.188+0.944
+Other Current Liabilities+Current Deferred Liabilities
=1.909+0
=9.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Acrivon Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Total Current Liabilities
Comparable Companies
TRVI VOR GLSI CDT DSGN ABSI ABOS NYMXF CDXS PLX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Website
https://www.acrivon.com
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Executives
Mary Miller officer: Chief Legal Officer C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen director, officer: President and CEO C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd 10 percent owner SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen officer: Chief Financial Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe officer: Chief Operating Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou 10 percent owner C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek director 28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin officer: Chief Medical Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson director, officer: EVP - Business Operations C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Acrivon Therapeutics (Acrivon Therapeutics) Headlines

From GuruFocus

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

By sperokesalga sperokesalga • 05-09-2023

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

By Marketwired • 09-05-2023

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Marketwired • 08-17-2023

Acrivon Therapeutics to Participate on a Panel at Cowen's 43rd Annual Health Care Conference

By sperokesalga sperokesalga • 02-27-2023

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

By GlobeNewswire • 09-19-2023

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

By sperokesalga sperokesalga • 04-25-2023

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

By sperokesalga sperokesalga • 03-28-2023

Acrivon Therapeutics Announces Pricing of Initial Public Offering

By Value_Insider Value_Insider • 11-15-2022

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

By Marketwired • 08-11-2023

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

By Marketwired • 10-16-2023